#USA #Actinium-225 #TerraPower #Hamilton, Ontario #AtomVie

Strategic Supply Agreement Between AtomVie and TerraPower Isotopes

In a significant advancement for the radiopharmaceutical landscape, AtomVie Global Radiopharma and TerraPower Isotopes, LLC have announced a strategic supply agreement on June 17, 2025. This groundbreaking partnership is set to enhance the development of radiopharmaceuticals via the reliable supply of high-quality Actinium-225 (Ac-225), a vital isotope in cancer treatment.

Enhancing Cancer Treatment Through Collaboration

The agreement focuses on strengthening AtomVie’s capabilities in contract development and manufacturing (CDMO) of radiopharmaceuticals. With TerraPower Isotopes providing its premium Actinium-225, AtomVie is poised to bolster its portfolio and help clients engage in global clinical and commercial projects more effectively. This collaboration promises to respond dynamically to the needs of pharmaceutical partners as they navigate through various stages of product development.

Bruno Paquin, the CEO of AtomVie, expressed enthusiasm about the partnership: "We are pleased to collaborate with TerraPower Isotopes to ensure the supply of Actinium-225 for our clients. This reinforces our ability to meet the evolving needs of our pharmaceutical partners, supporting their programs from development all the way to commercial supply. Together, we drive innovative therapies that enhance the quality of life for patients worldwide."

Scott Claunch, president of TerraPower Isotopes, echoed these sentiments, stating, "Working with AtomVie enables us to propel the next generation of targeted radiopharmaceutical therapies. Combining our extreme purity Ac-225 access with their development and manufacturing capabilities, we are proud to play a key role in expanding treatments that have the potential to improve patient outcomes."

Reliable Supply to Accelerate Research and Development

The agreement aims to secure a dependable supply of Actinium-225, crucial for both early and late-stage development programs. This reliability enhances the flexibility and responsiveness of AtomVie during the entire product development cycle. By ensuring a consistent source of this important isotope, AtomVie can facilitate smoother transitions from initial research phases to clinical trials and eventual market launch.

The commitment to innovation in nuclear medicine is shared by both organizations, as this agreement stands as a testament to their dedication to advancing cutting-edge radiotherapies. The ultimate goal is to expand global access to these vital treatments, enhancing the prospects for patients battling cancer and other serious diseases.

About AtomVie Global Radiopharma

AtomVie is recognized as a leader in the manufacturing of clinical and commercial radiopharmaceuticals, operating under stringent good manufacturing practices (GMP) standards. This company handles a wide array of scientific, technical, regulatory, quality, and logistical services, providing specialized infrastructure for radiopharmaceutical development. AtomVie services clients engaged in clinical studies across over 25 nations and is currently developing a state-of-the-art facility in Hamilton, Ontario, set to open by late 2025.

About TerraPower Isotopes

TerraPower Isotopes is on the frontier of isotope innovation, as a subsidiary of TerraPower, a major player in nuclear innovation. They focus on the development of advanced radioisotope generators that facilitate the efficient extraction of rare isotopes with life-saving potential. By enhancing global access to Actinium-225, they are positioned to help improve cancer treatments that target specific cancerous cells while minimizing harm to healthy tissues.

Conclusion

The strategic supply agreement between AtomVie and TerraPower Isotopes marks a pivotal movement towards improving the therapeutic landscape for cancer treatments. As these organizations work together to deliver high-quality radiopharmaceuticals powered by Actinium-225, they strive to meet the medical community's needs and elevate patient care standards globally.